Safety and Efficacy of VIT against Wasp Venom in Ultra-Rush Protocols in Patients Older Than 60 Years.

Background: Allergen immunotherapy remains a widely recognized and widely used method for the treatment of selected allergic diseases. Currently, according to the European Academy Of Allergy and Clinical Immunology (EAACI) guidelines, venom immunotherapy (VIT) may be considered for patients over 60. Nevertheless, no separate studies have confirmed the efficacy and safety of this therapy.

Different Development Forms of Local Allergic Rhinitis towards Birch.

Background: Efficacy of allergen immunotherapy (AIT) in local allergic rhinitis (LAR) is a new subject of research. The presence of asthmatic symptoms in patients with LAR in the context of AIT is unexplored.

Objective: The efficacy and safety of AIT in patients with LAR towards birch pollen were investigated.

Montelukast's ability to fight COVID-19 infection.

Montelukast can be effective in the treatment of SARS-CoV-2 infection.